Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
Sub-optimally controlled Type 2 Diabetes Mellitus (T2DM) patients treated with insulin glargine for a minimum of 3 months:
- Sub-optimal: HbA1c level >7% and fasting blood glucose <130mg/dL
- Male or Female ≥18 years old
- Body Mass Index (BMI) <40
- 10% ≥HbA1c ≥7%
- If taking Oral anti-diabetics (OADs), must be on stable dose for at least 1 months
- Patients willing to sign data release consent form
Exclusion criteria:
- Diabetes other than T2DM
- Enrolled in other clinical trials
- Previous treatment with an insulin other than insulin glargine
- Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or with Di Peptidyl Peptidase 4 (DPP-IV) inhibitors
- Pregnant or lactating women
- Contraindicated to Lantus (insulin glargine) / Apidra (insulin glulisine) / Novomix 30 (insulin aspart)
- Treatment with systemic corticoid steroids within the last 3 months prior to study enter
- Treatment with any investigational product within the last 3 months prior to study entry
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Administrative Office
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
group 1: Basal plus
group 2: Biphasic insulin
Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).